Prognosis Factors in Patients with Copd and Atrial Fibrillation – Mini Review

1 Radovanovic D, Contoli M, Braido F, Maniscalco M, Micheletto C, Solidoro P, Santus P, Carone M. Future Perspectives of Revaluating Mild COPD. Respiration. 2022; 101(7):688-696. Search in Google Scholar

2 Sandelowsky H, Weinreich UM, Aarli BB, et al. COPD -do the right thing. BMC Fam Pract. 2021; 22(1):244. Search in Google Scholar

3 Ulmeanu R, Fildan AP, Rajnoveanu RM, et al. Romanian clinical guideline for diagnosis and treatment of COPD. J Int Med Res 2020; 48(8): 300060520946907. Search in Google Scholar

4 Simons SO, Elliott A, Sastry M, et al. Chronic obstructive pulmonary disease and atrial fibrillation: an interdisciplinary perspective. Eur Heart J. 2021; 42(5):532-540. Search in Google Scholar

5 Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007; 370:741–750. Search in Google Scholar

6 Sandelowsky H, Ställberg B, Nager A, Hasselström J. The prevalence of undiagnosed chronic obstructive pulmonary disease in a primary care population with respiratory tract infections - a case fnding study. BMC Fam Pract. 2011; 12:122. Search in Google Scholar

7 Kaplan A, Thomas M. Screening for COPD: the gap between logic and evidence. Eur Respir Rev. 2017;26(143):160113. Search in Google Scholar

8 Grymonprez M, Vakaet V, Kavousi M, et al. Chronic obstructive pulmonary disease and the development of atrial fibrillation. Int J Cardiol. 2019; 276:118-124. Search in Google Scholar

9 Chao TF, Hung CL, Chen SJ, et al. The association between hyperuricemia, left atrial size and new-onset atrial fibrillation. Int J Cardiol. 2013; 168(4):4027-32. Search in Google Scholar

10 McManus DD, Yin X, Gladstone R, et al. Alcohol Consumption, Left Atrial Diameter, and Atrial Fibrillation. J Am Heart Assoc. 2016; 5(9):e004060. Search in Google Scholar

11 van der Velden RMJ, Hermans ANL, Pluymaekers NAHA, et al. Dyspnea in patients with atrial fibrillation: Mechanisms, assessment and an interdisciplinary and integrated care approach. Int J Cardiol Heart Vasc. 2022; 42:101086. Search in Google Scholar

12 Guerra F, Brambatti M, Nieuwlaat R, et al. Symptomatic atrial fibrillation and risk of cardiovascular events: data from the Euro Heart Survey. Europace. 2017; 19(12):1922-9. Search in Google Scholar

13 Tsigkas G, Apostolos A, Despotopoulos S, et al. Heart failure and atrial fibrillation: new concepts in pathophysiology, management, and future directions, Heart Fail Rev. 2022; 27(4): 1201–1210. Search in Google Scholar

14 Romiti GF, Corica B, Pipitone E, et al. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: a systematic review and meta-analysis of 4,200,000 patients. Eur Heart J. 2021; 14;42(35):3541-3554. Search in Google Scholar

15 Aisanov Z, Khaltaev N. Management of cardiovascular comorbidities in chronic obstructive pulmonary disease patients. J Thorac Dis. 2020; 12(5):2791-2802. Search in Google Scholar

16 Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011; 378:1015-26. Search in Google Scholar

17 Papaioannou AI, Mazioti A, Kiropoulos T, et al. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respir Med 2010; 104:275-82. Search in Google Scholar

18 Van Wagoner DR, Chung MK. Inflammation, Inflammasome Activation, and Atrial Fibrillation. Circulation. 2018; 138(20):2243-2246. Search in Google Scholar

19 Marcus GM, Smith LM, Ordovas K, et al. Intra and extracardiac markers of inflammation during atrial fibrillation. Heart Rhythm. 2010; 7:149–154. Search in Google Scholar

20 Zhou X, Dudley SC Jr. Evidence for Inflammation as a Driver of Atrial Fibrillation. Front Cardiovasc Med. 2020; 7:62. Search in Google Scholar

21 Rabe KF, Celli BR, Wechsler ME, et al. Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial. Lancet Respir. Med. 2021; 9(11): 1288–1298. Search in Google Scholar

22 Matarazzo L, Hernandez Santana YE, Walsh PT, Fallon PG. The IL-1 cytokine family as custodians of barrier immunity. Cytokine. 2022; 154:155890. Search in Google Scholar

23 Hak Ł, Myśliwska J, Wieckiewicz J, et al. Interleukin-2 as a predictor of early postoperative atrial fibrillation after cardiopulmonary bypass graft (CABG). J Interferon Cytokine Res. 2009; 29(6):327-32. Search in Google Scholar

24 Conway DS, Buggins P, Hughes E, Lip GY. Relationship of interleukin-6 and C-reactive protein to the prothrombotic state in chronic atrial fibrillation. J Am Coll Cardiol. 2004; 148:462–466. Search in Google Scholar

25 Hlapčić I, Belamarić D, Bosnar M, et al. Combination of Systemic Inflammatory Biomarkers in Assessment of Chronic Obstructive Pulmonary Disease: Diagnostic Performance and Identification of Networks and Clusters. Diagnostics (Basel). 2020; 10(12):1029. Search in Google Scholar

26 Rennard SI, Locantore N, Delafont B, et al. Identification of Five Chronic Obstructive Pulmonary Disease Subgroups with Different Prognoses in the ECLIPSE Cohort Using Cluster Analysis. Ann Am Thorac Soc. 2015; 12: 303–312. Search in Google Scholar

27 Tyrrell DJ, Goldstein DR. Ageing and atherosclerosis: vascular intrinsic and extrinsic factors and potential role of IL-6. Nat Rev Cardiol. 2021; 18(1):58-68. Search in Google Scholar

28 Ridker PM, Libby P, MacFadyen JG, et al. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018; 39(38):3499-3507. Search in Google Scholar

29 Rafaqat S, Sharif S, Majeed M, et al. Biomarkers of Metabolic Syndrome: Role in Pathogenesis and Pathophysiology Of Atrial Fibrillation. J Atr Fibrillation. 2021; 14(2):20200495. Search in Google Scholar

30 Psychari SN, Apostolou TS, Sinos L, et al. Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation. Am J Cardiol. 2005; 95(6):764–767. Search in Google Scholar

31 Liuba I, Ahlmroth H, Jonasson L, et al. Source of inflammatory markers in patients with atrial fibrillation. Europace. 2008; 10(7):848-53. Search in Google Scholar

32 Miller J, Edwards LD, Agustí A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir Med 2013; 107:1376–84. Search in Google Scholar

33 Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363:1128–38. Search in Google Scholar

34 Fermont JM, Masconi KL, Jensen MT, et al. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis. Thorax. 2019; 74(5):439-446. Search in Google Scholar

35 Celli BR, Locantore N, Yates J, et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185:1065–72. Search in Google Scholar

36 Zeng YY, Hu WP, Zuo YH, Wang XR, Zhang J. Altered serum levels of type I collagen turnover indicators accompanied by IL-6 and IL-8 release in stable COPD. Int J Chron Obstruct Pulmon Dis. 2019; 14:163-168. Search in Google Scholar

37 Regan EA, Hersh CP, Castaldi PJ, et al. Omics and the Search for Blood Biomarkers in Chronic Obstructive Pulmonary Disease. Insights from COPDGene. Am J Respir Cell Mol Biol. 2019; 61(2):143-149. Search in Google Scholar

38 Shyam Prasad Shetty B, Chaya SK, Kumar V S, et al. Inflammatory Biomarkers Interleukin 1 Beta (IL-1β) and Tumour Necrosis Factor Alpha (TNF-α) Are Differentially Elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD. Toxics. 2021; 9(4):72. Search in Google Scholar

39 Eagan TM, Gabazza EC, D'Alessandro-Gabazza C, et al. TNF-α is associated with loss of lean body mass only in already cachectic COPD patients. Respir Res. 2012; 13(1):48. Search in Google Scholar

40 Shyam Prasad Shetty B, Chaya SK, Kumar V S, et al. Inflammatory Biomarkers Interleukin 1 Beta (IL-1β) and Tumour Necrosis Factor Alpha (TNF-α) Are Differentially Elevated in Tobacco Smoke Associated COPD and Biomass Smoke Associated COPD. Toxics. 2021; 9(4): 72. Search in Google Scholar

41 Derella CC, Tingen MS, Blanks A, et al. Smoking cessation reduces systemic inflammation and circulating endothelin-1. Sci Rep. 2021; 11(1):24122. Search in Google Scholar

42 Terzano C, Romani S, Conti V, et al. Atrial fibrillation in the acute, hypercapnic exacerbations of COPD. Eur Rev Med Pharmacol Sci. 2014; 18(19):2908-17. Search in Google Scholar

43 Goudis CA. Chronic obstructive pulmonary disease and atrial fibrillation: An unknown relationship. J Cardiol. 2017; 69(5):699-705. Search in Google Scholar

44 Bodez D, Damy T, Soulat-Dufour L, Meuleman C, Cohen A. Consequences of obstructive sleep apnoea syndrome on left ventricular geometry and diastolic function. Arch Cardiovasc Dis. 2016; 109(8–9):494–503. Search in Google Scholar

45 Pauklin P, Zilmer M, Eha J, et al. Markers of Inflammation, Oxidative Stress, and Fibrosis in Patients with Atrial Fibrillation. Oxid Med Cell Longev. 2022; 2022:4556671. Search in Google Scholar

46 Liguori I, Russo G, Curcio F, et al. Oxidative stress, aging, and diseases. Clin Interv Aging. 2018; 13:757-772. Search in Google Scholar

47 Choudhury G, MacNee W. Role of inflammation and oxidative stress in the pathology of ageing in COPD: potential therapeutic interventions. COPD. 2017; 14(1):122–135. Search in Google Scholar

48 Liu CC, Chen YH, Chang YH, et al. New-Onset Atrial Fibrillation Is a Risk Factor of Ischemic Stroke in Chronic Obstructive Pulmonary Disease. Healthcare (Basel). 2022; 10(2):381. Search in Google Scholar